| Literature DB >> 20472028 |
Bruce Y Lee1, Paul J Ufberg, Rachel R Bailey, Ann E Wiringa, Kenneth J Smith, Andrew J Nowalk, Conor Higgins, Angela R Wateska, Robert R Muder.
Abstract
The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (<or=$500), and S. aureus attack rates (>or=1%). (c) 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20472028 PMCID： PMC2896294 DOI： 10.1016/j.vaccine.2010.04.069
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641